SI3368044T1 - Zdravljenje oligoovulacije, povezane s steatozo jeter - Google Patents

Zdravljenje oligoovulacije, povezane s steatozo jeter

Info

Publication number
SI3368044T1
SI3368044T1 SI201631327T SI201631327T SI3368044T1 SI 3368044 T1 SI3368044 T1 SI 3368044T1 SI 201631327 T SI201631327 T SI 201631327T SI 201631327 T SI201631327 T SI 201631327T SI 3368044 T1 SI3368044 T1 SI 3368044T1
Authority
SI
Slovenia
Prior art keywords
ovulation
treatment
hepatic steatosis
related oligo
steatosis related
Prior art date
Application number
SI201631327T
Other languages
English (en)
Inventor
Lourdes Ibanez
Zegher Francis De
Original Assignee
Katholieke Universiteit Leuven K.U. Leuven R&D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven K.U. Leuven R&D filed Critical Katholieke Universiteit Leuven K.U. Leuven R&D
Publication of SI3368044T1 publication Critical patent/SI3368044T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI201631327T 2015-10-27 2016-10-27 Zdravljenje oligoovulacije, povezane s steatozo jeter SI3368044T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
EP16788501.1A EP3368044B1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
SI3368044T1 true SI3368044T1 (sl) 2022-05-31

Family

ID=55130283

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631327T SI3368044T1 (sl) 2015-10-27 2016-10-27 Zdravljenje oligoovulacije, povezane s steatozo jeter

Country Status (24)

Country Link
US (2) US20190060328A1 (sl)
EP (2) EP3892281A3 (sl)
JP (2) JP6999903B2 (sl)
KR (1) KR102608158B1 (sl)
CN (2) CN117379440A (sl)
AR (1) AR106505A1 (sl)
AU (1) AU2016344737C1 (sl)
BR (1) BR112018008496A2 (sl)
CA (1) CA3003076C (sl)
DK (1) DK3368044T3 (sl)
ES (1) ES2883282T3 (sl)
GB (1) GB201518979D0 (sl)
HU (1) HUE055778T2 (sl)
IL (1) IL258876B (sl)
LT (1) LT3368044T (sl)
MA (2) MA54412A (sl)
MX (2) MX2018005252A (sl)
PL (1) PL3368044T3 (sl)
RS (1) RS62764B1 (sl)
RU (1) RU2745606C2 (sl)
SI (1) SI3368044T1 (sl)
TW (1) TWI791420B (sl)
UY (1) UY36967A (sl)
WO (1) WO2017072243A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200090927A (ko) 2017-12-19 2020-07-29 아카우오스, 인크. 내이에 대한 치료적 항체의 aav-매개 전달
CA3107945A1 (en) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
MX2022014204A (es) 2020-05-13 2023-04-14 Akouos Inc Composiciones y metodos para tratar la perdida auditiva asociada al gen slc26a4.
PE20240115A1 (es) 2020-12-01 2024-01-22 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular
PE20240012A1 (es) 2020-12-29 2024-01-04 Akouos Inc Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
JP2006520747A (ja) * 2002-12-11 2006-09-14 アミリン・ファーマシューティカルズ，インコーポレイテッド 多嚢胞性卵巣症候群を治療するための方法および組成物
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
CA3107945A1 (en) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome

Also Published As

Publication number Publication date
AR106505A1 (es) 2018-01-24
EP3368044A1 (en) 2018-09-05
MA43106A (fr) 2021-05-05
RU2018119146A3 (sl) 2020-02-25
HUE055778T2 (hu) 2021-12-28
MA43106B1 (fr) 2021-09-30
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
KR20180098234A (ko) 2018-09-03
MX2021007976A (es) 2021-08-16
UY36967A (es) 2017-05-31
RU2745606C2 (ru) 2021-03-29
WO2017072243A8 (en) 2018-03-22
AU2016344737B2 (en) 2021-07-08
WO2017072243A1 (en) 2017-05-04
JP2019501113A (ja) 2019-01-17
KR102608158B1 (ko) 2023-11-29
EP3368044B1 (en) 2021-06-09
US20240000804A1 (en) 2024-01-04
RS62764B1 (sr) 2022-01-31
DK3368044T3 (da) 2021-09-13
TWI791420B (zh) 2023-02-11
AU2016344737C1 (en) 2021-10-07
CA3003076C (en) 2023-12-05
IL258876A (en) 2018-06-28
AU2016344737A1 (en) 2018-05-17
EP3892281A3 (en) 2021-11-10
MX2018005252A (es) 2018-09-18
AU2016344737A9 (en) 2018-08-09
JP2022009374A (ja) 2022-01-14
US20190060328A1 (en) 2019-02-28
BR112018008496A2 (pt) 2018-10-23
TW201720432A (zh) 2017-06-16
CA3003076A1 (en) 2017-05-04
IL258876B (en) 2022-03-01
RU2018119146A (ru) 2019-11-28
EP3892281A2 (en) 2021-10-13
CN108778285A (zh) 2018-11-09
GB201518979D0 (en) 2015-12-09
LT3368044T (lt) 2021-10-25
PL3368044T3 (pl) 2021-12-20
WO2017072243A9 (en) 2018-07-26
JP6999903B2 (ja) 2022-02-04
MA54412A (fr) 2021-11-10

Similar Documents

Publication Publication Date Title
IL259110A (en) Treatment of osteoarthritis (osteoarthritis)
HK1254287A1 (zh) 纖維化治療
HK1247823A1 (zh) 骨質疏鬆的治療
SG11201706729SA (en) Derivatives of sobetirome
GB201701673D0 (en) Methods of well treatment
IL258876B (en) Treatment of fatty liver associated with low ovulation
HK1259347A1 (zh) 治療結腸炎的方法
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
ZA201706282B (en) Solid forms of menaquinols
HK1256902A1 (zh) 氯犬尿氨酸的前體藥物
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
GB201604627D0 (en) Improved method of FT-IMS
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
IL255498A (en) Treatment of pruritus
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201513922D0 (en) Treatment of hyperpigmentation
GB201511017D0 (en) Method of treatment
GB201501277D0 (en) Kit of parts
GB201501238D0 (en) Kit of parts
GB201407806D0 (en) Treatment of fibrosis